193 related articles for article (PubMed ID: 9742919)
1. Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector.
Yoon SS; Carroll NM; Chiocca EA; Tanabe KK
Ann Surg; 1998 Sep; 228(3):366-74. PubMed ID: 9742919
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus.
Carroll NM; Chiocca EA; Takahashi K; Tanabe KK
Ann Surg; 1996 Sep; 224(3):323-9; discussion 329-30. PubMed ID: 8813260
[TBL] [Abstract][Full Text] [Related]
3. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma.
Yoon SS; Nakamura H; Carroll NM; Bode BP; Chiocca EA; Tanabe KK
FASEB J; 2000 Feb; 14(2):301-11. PubMed ID: 10657986
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene.
Boviatsis EJ; Park JS; Sena-Esteves M; Kramm CM; Chase M; Efird JT; Wei MX; Breakefield XO; Chiocca EA
Cancer Res; 1994 Nov; 54(22):5745-51. PubMed ID: 7954393
[TBL] [Abstract][Full Text] [Related]
5. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene.
Pawlik TM; Nakamura H; Mullen JT; Kasuya H; Yoon SS; Chandrasekhar S; Chiocca EA; Tanabe KK
Cancer; 2002 Sep; 95(5):1171-81. PubMed ID: 12209705
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy.
Kramm CM; Chase M; Herrlinger U; Jacobs A; Pechan PA; Rainov NG; Sena-Esteves M; Aghi M; Barnett FH; Chiocca EA; Breakefield XO
Hum Gene Ther; 1997 Nov; 8(17):2057-68. PubMed ID: 9414254
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer.
Kasuya H; Nishiyama Y; Nomoto S; Hosono J; Takeda S; Nakao A
J Surg Oncol; 1999 Nov; 72(3):136-41. PubMed ID: 10562359
[TBL] [Abstract][Full Text] [Related]
8. The effect of ganciclovir on herpes simplex virus-mediated oncolysis.
Carroll NM; Chase M; Chiocca EA; Tanabe KK
J Surg Res; 1997 May; 69(2):413-7. PubMed ID: 9224416
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation.
Spear MA; Sun F; Eling DJ; Gilpin E; Kipps TJ; Chiocca EA; Bouvet M
Cancer Gene Ther; 2000 Jul; 7(7):1051-9. PubMed ID: 10917208
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic viral therapy for human ovarian cancer using a novel replication-competent herpes simplex virus type I mutant in a mouse model.
Nawa A; Nozawa N; Goshima F; Nagasaka T; Kikkawa F; Niwa Y; Nakanishi T; Kuzuya K; Nishiyama Y
Gynecol Oncol; 2003 Oct; 91(1):81-8. PubMed ID: 14529666
[TBL] [Abstract][Full Text] [Related]
12. Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses.
Wildner O; Morris JC
J Gene Med; 2000; 2(5):353-60. PubMed ID: 11045429
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy using tissue-specific replication competent HSV.
Miyatake S
Hum Cell; 2002 Sep; 15(3):130-7. PubMed ID: 12703543
[TBL] [Abstract][Full Text] [Related]
14. Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan.
Wildner O; Blaese RM; Morris JC
Hum Gene Ther; 1999 Nov; 10(16):2679-87. PubMed ID: 10566896
[TBL] [Abstract][Full Text] [Related]
15. Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase.
Moriuchi S; Oligino T; Krisky D; Marconi P; Fink D; Cohen J; Glorioso JC
Cancer Res; 1998 Dec; 58(24):5731-7. PubMed ID: 9865731
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Akbulut H; Zhang L; Tang Y; Deisseroth A
Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
[TBL] [Abstract][Full Text] [Related]
17. Retrovirus-mediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo.
Nishihara E; Nagayama Y; Mawatari F; Tanaka K; Namba H; Niwa M; Yamashita S
Endocrinology; 1997 Nov; 138(11):4577-83. PubMed ID: 9348181
[TBL] [Abstract][Full Text] [Related]
18. Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine.
Toda M; Martuza RL; Rabkin SD
Gene Ther; 2001 Feb; 8(4):332-9. PubMed ID: 11313808
[TBL] [Abstract][Full Text] [Related]
19. Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases.
Nomura N; Kasuya H; Watanabe I; Shikano T; Shirota T; Misawa M; Sugimoto H; Kanazumi N; Nomoto S; Takeda S; Nakao A
Cancer Chemother Pharmacol; 2009 Jan; 63(2):321-30. PubMed ID: 18575868
[TBL] [Abstract][Full Text] [Related]
20. Tumor reduction in vivo after adenoviral mediated gene transfer of the herpes simplex virus thymidine kinase gene and ganciclovir treatment in human head and neck squamous cell carcinoma.
Goebel EA; Davidson BL; Graham SM; Kern JA
Otolaryngol Head Neck Surg; 1998 Oct; 119(4):331-6. PubMed ID: 9781985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
